Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

gilead sciences switzerland sàrl - idelalisibum - filmtabletten - idelalisibum 150 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 1.085 mg. - onkologikum - synthetika

Austria - Kijerumani - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ebewe pharma ges.m.b.h. nfg.kg - epirubicin hydrochlorid - epirubicin

Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - kapseln - ibrutinibum 140 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172, propylenglycolum, pro capsula corresp. natrium 2.73 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - bendamustinhydrochlorid - pulver für ein konzentrat zur herstellung einer infusionslösung - teil 1 - pulver für ein konzentrat zur herstellung einer infusionslösung; bendamustinhydrochlorid (36755) 2,5 milligramm

Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 140 mg, lactosum monohydricum 28 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 1.14 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 280 mg, lactosum monohydricum 56 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp., natrium 2.28 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 420 mg, lactosum monohydricum 84 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 3.42 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Uswisi - Kijerumani - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 560 mg, lactosum monohydricum 112 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 4.56 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika

Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastische mittel - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiples myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.